Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02442479 · ClinicalTrials.gov registry record · NA

Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults

A NA study, sponsored by University of Alabama at Birmingham.

Completed
Registry status
NA
Development phase
127
Enrollment target

NCT02442479 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 127 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02442479, a NA study, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
NA
Development phase
127 participants
Enrollment target

Study Summary

Resistance training has shown the most promise among interventions aimed to combat aging muscle atrophy as it enhances strength, power, and mobility function, but induces varying degrees of skeletal muscle hypertrophy as the investigators demonstrated in the initial 5-year funding period of this award (2001-2006). In the subsequent 5-year funding period (2007-2012), the investigators built on this prior work by using a dose-response approach in older adults - ultimately to optimize the treatment of age-related muscle atrophy. The investigators tested four, long-term resistance training prescriptions in older (60-75 yr) women and men to determine which prescription maximizes mechanisms driving muscle regrowth. One of the innovations in this project was the use of a 4-wk pre-training program to reach a plateau in the early, non-muscle mass adaptations, thereby establishing a true baseline from which both mechanisms of measurable muscle hypertrophy and functional consequences of hypertrophy could be studied in a tightly integrated fashion without bias in the subsequent experimental period. A randomized design was used to test the overarching hypothesis that a novel program of mixed strength and power training would optimize the anabolic environment to promote muscle hypertrophy and robust gains in performance. This hypothesis was tested with three specific aims.

Interventions

  • BEHAVIORAL resistance training

Trial Details

FieldValue
Enrollment Target 127 participants
Start Date 2007-04
Est. Completion 2013-03
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT02442479

The ClinicalTrials.gov registry entry for NCT02442479 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which resistance training is the first listed.

NCT02442479 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02442479 about?

NCT02442479 is a clinical study titled "Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults". Resistance training has shown the most promise among interventions aimed to combat aging muscle atrophy as it enhances strength, power, and mobility function, but induces varying degrees of skeletal muscle hypertrophy as the investigators demonstrated in the initial 5-year funding period of this awa...

What is the current status of trial NCT02442479?

This trial is currently completed. It is a NA study. The enrollment target is 127 participants. The study started on 2007-04. Estimated completion is 2013-03.

What interventions are being tested in trial NCT02442479?

The interventions under investigation include: resistance training (BEHAVIORAL).

Who is sponsoring clinical trial NCT02442479?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.